Clinical trial
PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or…
NCT00348985 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00348985 |
|---|---|
| Title | PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas |
| Official title | A Phase 1 Study of PXD101 in Combination With Bortezomib (PS-341) in Patients With Advanced Solid Tumors and Lymphoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Adult Grade III Lymphomatoid Granulomatosis, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Post-transplant Lymphoproliferative Disorder, Primary Central Nervous System Hodgkin Lymphoma, Primary Central Nervous System Non-Hodgkin Lymphoma, Recurrent Adult Burkitt Lymphoma and 52 more |
| Intervention type | Drug, Other |
| Interventions | belinostat, bortezomib, pharmacological study |
| Enrollment | 55 |
| Start date | Mar 1, 2006 |
| Primary completion | Jan 1, 2010 |
| First posted | Jul 6, 2006 |
| Last update posted | May 3, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: